Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia.
Tschaidse L, Reisch N, Arlt W, Brac de la Perriere A, Linden Hirschberg A, Juul A, Mallappa A, Merke DP, Newell-Price JDC, Perry CG, Prete A, Rees DA, Stikkelbroeck NMML, Touraine PA, Coope H, Porter J, Ross RJM, Quinkler M.
Tschaidse L, et al. Among authors: coope h.
Eur J Endocrinol. 2023 Jan 10;188(1):lvac006. doi: 10.1093/ejendo/lvac006.
Eur J Endocrinol. 2023.
PMID: 36654495
Free article.